Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jul;40(7):1657–1664. doi: 10.1128/aac.40.7.1657

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

R T Davey Jr 1, D G Chaitt 1, G F Reed 1, W W Freimuth 1, B R Herpin 1, J A Metcalf 1, P S Eastman 1, J Falloon 1, J A Kovacs 1, M A Polis 1, R E Walker 1, H Masur 1, J Boyle 1, S Coleman 1, S R Cox 1, L Wathen 1, C L Daenzer 1, H C Lane 1
PMCID: PMC163391  PMID: 8807058

Abstract

Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human immunodeficiency virus type 1. In the present phase I/II study we evaluated the safety, toxicity, pharmacokinetics, and antiretroviral activities of two-drug and three-drug combinations of DLV and conventional doses of nucleoside analogs compared with those of both DLV monotherapy and two-drug nucleoside analog therapy. A total of 85 human immunodeficiency virus type 1 infected patients with CD4 counts of 100 to 300 cells per mm3 were enrolled in two periods: in the first period patients were randomized to receive either zidovudine (ZDV) plus didanosine (group 1) or ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of DLV (group 2). In the second period, patients were randomized to receive either 1,200 mg of DLV alone per day (group 3) or ZDV plus 1,200 mg of DLV per day (group 4). DLV demonstrated good oral bioavailability at all five doses tested. The major toxicity was a transient mild rash which appeared in 44% of all DLV recipients. Overall, group 2 patients demonstrated more sustained improvements in CD4 counts, percent CD4 cells, branched DNA levels, p24 antigen levels, and virus titers in plasma than group 1, 3, or 4 patients. The magnitude of the response correlated with the intensity of prior nucleoside analog treatment, the non-syncytium-inducing or syncytium-inducing viral phenotype at baseline, and the presence of a wild-type codon at amino acid position 215 in the baseline reverse transcriptase genotype. Despite a transient rash, DLV therapy was well tolerated. Combination therapy with DLV and nucleoside analogs appears promising, with the three-drug combination appearing to be more potent that either two-drug combinations or monotherapy.

Full Text

The Full Text of this article is available as a PDF (290.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balzarini J., Karlsson A., Pérez-Pérez M. J., Camarasa M. J., Tarpley W. G., De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol. 1993 Sep;67(9):5353–5359. doi: 10.1128/jvi.67.9.5353-5359.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cheeseman S. H., Havlir D., McLaughlin M. M., Greenough T. C., Sullivan J. L., Hall D., Hattox S. E., Spector S. A., Stein D. S., Myers M. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141–151. [PubMed] [Google Scholar]
  3. D'Aquila R. T., Johnson V. A., Welles S. L., Japour A. J., Kuritzkes D. R., DeGruttola V., Reichelderfer P. S., Coombs R. W., Crumpacker C. S., Kahn J. O. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15;122(6):401–408. doi: 10.7326/0003-4819-122-6-199503150-00001. [DOI] [PubMed] [Google Scholar]
  4. Davey R. T., Jr, Dewar R. L., Reed G. F., Vasudevachari M. B., Polis M. A., Kovacs J. A., Falloon J., Walker R. E., Masur H., Haneiwich S. E. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5608–5612. doi: 10.1073/pnas.90.12.5608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davey R. T., Jr, Lane H. C. Laboratory methods in the diagnosis and prognostic staging of infection with human immunodeficiency virus type 1. Rev Infect Dis. 1990 Sep-Oct;12(5):912–930. doi: 10.1093/clinids/12.5.912. [DOI] [PubMed] [Google Scholar]
  6. Dewar R. L., Highbarger H. C., Sarmiento M. D., Todd J. A., Vasudevachari M. B., Davey R. T., Jr, Kovacs J. A., Salzman N. P., Lane H. C., Urdea M. S. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis. 1994 Nov;170(5):1172–1179. doi: 10.1093/infdis/170.5.1172. [DOI] [PubMed] [Google Scholar]
  7. Dueweke T. J., Kézdy F. J., Waszak G. A., Deibel M. R., Jr, Tarpley W. G. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 1992 Jan 5;267(1):27–30. [PubMed] [Google Scholar]
  8. Dueweke T. J., Poppe S. M., Romero D. L., Swaney S. M., So A. G., Downey K. M., Althaus I. W., Reusser F., Busso M., Resnick L. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 1993 May;37(5):1127–1131. doi: 10.1128/aac.37.5.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dueweke T. J., Pushkarskaya T., Poppe S. M., Swaney S. M., Zhao J. Q., Chen I. S., Stevenson M., Tarpley W. G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4713–4717. doi: 10.1073/pnas.90.10.4713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eastman P. S., Boyer E., Mole L., Kolberg J., Urdea M., Holodniy M. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol. 1995 Oct;33(10):2777–2780. doi: 10.1128/jcm.33.10.2777-2780.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fan N., Evans D. B., Rank K. B., Thomas R. C., Tarpley W. G., Sharma S. K. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Lett. 1995 Feb 13;359(2-3):233–238. doi: 10.1016/0014-5793(95)00051-a. [DOI] [PubMed] [Google Scholar]
  12. Havlir D., Cheeseman S. H., McLaughlin M., Murphy R., Erice A., Spector S. A., Greenough T. C., Sullivan J. L., Hall D., Myers M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995 Mar;171(3):537–545. doi: 10.1093/infdis/171.3.537. [DOI] [PubMed] [Google Scholar]
  13. Holodniy M., Mole L., Margolis D., Moss J., Dong H., Boyer E., Urdea M., Kolberg J., Eastman S. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Virol. 1995 Jun;69(6):3510–3516. doi: 10.1128/jvi.69.6.3510-3516.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koot M., Keet I. P., Vos A. H., de Goede R. E., Roos M. T., Coutinho R. A., Miedema F., Schellekens P. T., Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993 May 1;118(9):681–688. doi: 10.7326/0003-4819-118-9-199305010-00004. [DOI] [PubMed] [Google Scholar]
  15. Pagano P. J., Chong K. T. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J Infect Dis. 1995 Jan;171(1):61–67. doi: 10.1093/infdis/171.1.61. [DOI] [PubMed] [Google Scholar]
  16. Reichman R. C., Morse G. D., Demeter L. M., Resnick L., Bassiakos Y., Fischl M., Para M., Powderly W., Leedom J., Greisberger C. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. J Infect Dis. 1995 Feb;171(2):297–304. doi: 10.1093/infdis/171.2.297. [DOI] [PubMed] [Google Scholar]
  17. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar;68(3):1660–1666. doi: 10.1128/jvi.68.3.1660-1666.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Richman D. D. Resistance, drug failure, and disease progression. AIDS Res Hum Retroviruses. 1994 Aug;10(8):901–905. doi: 10.1089/aid.1994.10.901. [DOI] [PubMed] [Google Scholar]
  19. Romero D. L., Busso M., Tan C. K., Reusser F., Palmer J. R., Poppe S. M., Aristoff P. A., Downey K. M., So A. G., Resnick L. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8806–8810. doi: 10.1073/pnas.88.19.8806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Volberding P. The need for additional options in the treatment of human immunodeficiency virus infection. J Infect Dis. 1995 Mar;171 (Suppl 2):S150–S154. doi: 10.1093/infdis/171.supplement_2.s150. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES